Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report.
Trygve HolmøyAntonie G BeiskeSvetozar ZarnovickyAija Zuleron MyroEgil RøsjøEmilia KertyPublished in: BMC neurology (2016)
This is the first report on severe exacerbation of inflammatory disease activity after discontinuation of natalizumab in LHON-MS, and suggests that late rebound activity can occur in these patients.
Keyphrases
- disease activity
- multiple sclerosis
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- white matter
- newly diagnosed
- chronic obstructive pulmonary disease
- ejection fraction
- oxidative stress
- chronic kidney disease
- prognostic factors
- case report
- ms ms
- peritoneal dialysis
- intensive care unit